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Abstract
Expression and purification of human membrane proteins for structural studies represent a great challenge. This is because
micro- to milligram amounts of pure isolated protein are required. To this aim, we successfully expressed the human vitamin
C transporter-1 (hSVCT1; SLC23A1) in Xenopus laevis oocytes and isolated highly pure protein in microgram amounts.
Recombinant hSVCT1 was functional when expressed in oocytes and glycosylated. Structural analysis of purified hSVCT1 by
transmission electron microscopy and single particle analysis unveiled its shape, dimensions and low-resolution structure as
well as the existence of a major monomeric and minor dimeric population. Chemical crosslinking of isolated oocyte
membranes containing expressed hSVCT1 indicated similar oligomeric states of hSVCT1 in lipid bilayers. This work reports
the first purification and structural analysis of a human SVCT protein and opens the way for future functional and structural
studies using purified hSVCT1.
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Introduction
Vitamin C (ascorbic acid, ascorbate) mediates a variety of
enzymatic reactions and acts as an antioxidant against oxidative
stress in tissues and cells by scavenging free radicals. In contrast to
most higher animals, humans are unable to synthetize L-ascorbic
acid, making dietary vitamin C intake essential [1]. This is because
of the deficiency of the L-gulono-gamma-lactone oxidase in
humans [1], the enzyme catalysing the last step in ascorbic acid
biosynthesis from glucose. A well-known human disease linked to
deficiency of vitamin C is scurvy. This compromises the synthesis
of collagen where vitamin C is required as an electron donor.
Other examples for enzymatic reactions involving vitamin C as a
cofactor are found in the biosynthesis of carnitine and norepi-
nephrine [2], in adrenal steroidgenesis [3] and in the amidation of
peptide hormones [2].
In humans vitamin C is transported across the plasma
membrane in a sodium-dependent manner by specialized mem-
brane proteins. These are the sodium-dependent vitamin C
transporters SVCT1 (SLC23A1) and SVCT2 (SLC23A2), which
are encoded by the SLC23 gene family [4]. This gene family also
includes the orphan transporter SVCT3 (SLC23A3) [4]. Phylo-
genetically, human SVCTs belong to the nucleobase-ascorbate
transporter (NAT) family [5], which consists of several hundreds of
proteins in all kingdoms of life. Although human SLC23 members
belong to the NAT family, no nucleobase transport activity has
been reported yet. Besides a distant bacterial NAT homologue [6],
no structural information is available on human SVCTs.
Hydropathy analysis of human SVCT1 (hSVCT1) suggests that
it consists of twelve putative transmembrane domains (TMDs) with
intracellular termini [7,8]. In the extracellular domains of
hSVCT1 the asparagine residues Asn138, Asn144 and Asn230
represent potential N-glycosylation sites [7]. Mutagenesis studies of
hSVCT1 expressed in COS-1 cells indicated that Asn138 and
Asn144 are functional glycosylation sites playing a role in transport
activity and targeting to the plasma membrane [8]. The highly
conserved proline residues on the extracellular loops between
TMD VII and TMD VIII are essential for structural stability and
transport activity [9]. SVCT1 co-transports sodium and ascorbate
with a 2:1 stoichiometry [10]. Km values of 65–237 mM were
reported [9]. SVCT1 is widely distributed in epithelial tissue of
kidney, liver, lung, intestine and skin, where it maintains the
whole-body ascorbic acid levels [4].
Variations in the human SLC23A1 and SLC23A2 genes were
analysed, and SLC23A2 was shown to be associated with
spontaneous preterm delivery [11]. In Slc23a1 knockout mice
death within a few minutes after birth was observed [12] indicating
the important role of this transporter in maintaining ascorbate
homeostasis in tissues and across the placenta [12,13].
SVCTs are promising targets for carrier-mediated prodrug
approaches. Recently, enhanced oral absorption and systemic
bioavailability of a novel prodrug of the anti-HIV protease
inhibitor saquinavir was demonstrated when conjugated to
vitamin C [14]. Although the protective and therapeutic effects
of ascorbate for different cancers are highly debatable, several
in vitro and in vivo studies point into these directions [15–17].
Numerous studies are available on the functional roles of
SVCT1 and SVCT2, because of their physiological, pharmaceu-
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tical and clinical significance. However, no structural studies have
been reported so far for SVCT1 and SVCT2. Structural
information is important to understand the working mechanisms
of these transporters at the molecular level. The primary
requirement towards structure determination of human SVCTs,
and human membrane proteins in general, is pure, homogeneous
and stable protein. The overexpression and purification of
eukaryotic and in particular human membrane proteins at levels
sufficient for structural studies is often an immense challenge [18].
In the present study, we successfully managed to express functional
hSVCT1 in Xenopus laevis oocytes and isolate highly pure
recombinant protein for structural analysis by negative stain-
transmission electron microscopy (TEM) and single particle
analysis (SPA). This is the first report describing the purification
of a human SVCT, and its low-resolution structure and oligomeric
states.
Materials and Methods
All animal experiments were in accordance with the Swiss
Animal Welfare Law and were approved by the Local Veterinary
Authority Bern (Veterina¨ramt Bern; Permit Number: BE 26/12).
Cloning of hSVCT1 into the pMJB08 Expression Vector
cDNA from hSVCT1 (UniProtKB entry: Q9UHI7) was cloned
by PCR from a carrier construct of our laboratory into the
pMJB08 expression vector [19]. The forward primer 59 GGG
GAA TTC ATG AGG GCC CAG GAG GAC CTC 39 and the
reverse primer 59 GGG AAG CTT TCA GAC CTT GGT GCA
CAC AGA TGC 39 were used. PCR products were digested with
the restriction enzymes EcoRI and HindIII, and ligated into the
pMJB08 vector [19]. The DNA construct was verified by
sequencing.
Expression of recombinant hSVCT1 using this construct results
in a protein with an N-terminal extension containing and starting
with i.) a decahistidine tag, ii.) a FLAG epitope, iii.) a PreScission
protease cleavage site and iv.) a hemagglutinin (HA) epitope. For
more details on pMJB08 see Bergeron et al. [19]. The calculated
molecular masses of recombinant hSVCT1 based on the amino
acid sequence are ,70.8 kDa (full-length) and ,67.2 kDa after
Prescission protease cleavage.
Protein Expression in Xenopus laevis Oocytes, Isolation of
Total Membranes from Oocytes and Protein Purification
Expression of hSVCT1 was performed as previously described
for other mammalian and human transporters by Bergeron et al.
(2011) [19]. This methodological report from our laboratory also
describes in great detail the used procedure for the isolation of
oocyte membranes containing expressed hSVCT1 and the
subsequent affinity purification.
Determination of Protein Concentration
The bicinchoninic acid (BCA) assay (Pierce, Thermo Scientific)
was used for the determination of protein concentrations in
isolated oocyte membranes and of purified hSVCT1.
SDS-PAGE and Immunoblotting of Recombinant hSVCT1
SDS-PAGE and Western blot analysis were performed using
6% SDS/polyacrylamide gels (e.g., Fig. 1A and Fig. 2). Gels of
isolated oocyte membranes and purified protein were run using
Tris-glycine and Tris-Tricine running buffers, respectively. For
Western blot analysis PVDF membranes (Immobilon-P Transfer
Membrane, Millipore), mouse monoclonal anti-HA antibody
(Sigma; primary antibody) and goat anti-mouse IgG (H+L) HRP
conjugate (Bio-Rad; secondary antibody) were used.
Radiotracer Uptake Transport Assay with Xenopus
Oocytes
For functional characterization of hSVCT1 expressed in frog
oocytes, oocytes were injected with 20 ng of hSVCT1 cRNA. As a
control, oocytes were injected with the same volume of water.
Oocytes were incubated in Barth’s Medium (MBM: 88 mM NaCl,
1 mM KCl, 2.4 mM NaHCO3, 0.82 mM MgSO4, 0.66 mM
NaNO3, 0.75 mM CaCl2, 10 mM HEPES-NaOH (pH 7.4)) and
supplemented with P/S antibiotics (GIBCOTM Penicillin-Strepto-
mycin liquid, Invitrogen) for three days at 18uC. On the fourth
day, 10 oocytes were transferred into a centrifuge tube with 200 ml
of MBM containing 0.5 mCi [14C]ascorbate at 450 mM final
concentration (specific activity 0.00535 Ci/mmol, Perkin Elmer).
After 15 min incubation at room temperature, the radioactive
liquid was removed from the tube, and the oocytes were washed
three times with 1 ml of cold MBM buffer. Oocytes were then
transferred individually into the wells of a 96 well plate and 50 ml
of 5% SDS solution was added. The wells with oocytes were sealed
and put on a shaker operated at 900 rpm for 25 min to lyse and
homogenize the oocytes. 150 ml of scintillation cocktail (Micro-
scint-40, Perkin Elmer) were added to each well. Finally, wells
were resealed and uptake counts were measured using a Packard
TopCount scintillation counter.
Figure 1. Expression and function of hSVCT1 in Xenopus
oocytes. (A) Western blot analysis of isolated membranes from three
oocytes expressing hSVCT1. Western blotting was performed using a
6% SDS/polyacrylamide gel and an anti-HA antibody. The prominent
band below the 75 kDa marker corresponds to recombinant hSVCT1
(calculated molecular mass based on the amino acid sequence: ,
71 kDa). A second, less prominent band between the 100 kDa and
150 kDa markers was assigned to dimeric hSVCT1. (B) Oocytes injected
with hSVCT1 cRNA mediate uptake of [14C]ascorbate in contrast to
control oocytes injected with water. Mean 6 SEM from 20 oocytes are
indicated (two independent experiments).
doi:10.1371/journal.pone.0076427.g001
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Deglycosylation of Purified hSVCT1
For deglycosylation, 40 ml (2.4 mg) of purified hSVCT1 in
20 mM Tris-HCl (pH 8), 150 mM NaCl, 0.05% Triton X-100
were incubated with 8 ml PNGase F (New England Biolabs; final
PNGase F concentration of 0.046 mg/ml) for 30 min at room
temperature. Similarly and as negative control, purified hSVCT1
was incubated in absence of PNGase F. For SDS-PAGE and
Western blot analysis, equal volumes of 56SDS sample buffer
were added to the two reaction mixtures. For Figure 2C, ,250 ng
of untreated and PNGase F-treated hSVCT1 were loaded on a
6% SDS/polyacrylamide gel, and subjected to SDS-PAGE and
immunoblotting.
Negative-stain TEM and SPA
Purified hSVCT protein at ,60 mg/ml was adsorbed for ,30
seconds to parlodion carbon-coated copper grids which were
rendered hydrophilic by glow discharge at low pressure in air.
Grids were washed with three drops of double-distilled water and
stained with two drops of 0.75% uranyl formate. Electron
micrographs were recorded at a magnification of x110,000 with
a Philips CM12 TEM operated at 80 kV and equipped with a
Morada 11 megapixel CCD camera (Soft Imaging System).
Single particle analysis and averaging of negatively stained,
purified hSVCT1 proteins were performed using the EMAN
software package [20]. The first Thon ring on power spectra of
CCD images selected for SPA was typically between (1.0 nm)21–
(1.8 nm)21. The best preserved 366 monomer top views and 455
dimer top views of hSVCT1 were picked from CCD images.
Individual reference free class averages of monomers and dimers
were calculated and used to compute the presented averages
(originating from 316 monomer and 387 dimer particles).
Averages were low-pass filtered to 2 nm resolution. No two-fold
symmetry was imposed to the dimer average (Fig. 3B, rightmost
frame).
Chemical Crosslinking of hSVCT1 in Isolated Oocyte
Membranes
Chemical crosslinking of hSVCT1 in isolated oocyte mem-
branes was performed with the homobifunctional amine-reactive
crosslinker disuccinimidyl tartrate (DST; spacer arm length: 6.4 A˚;
Pierce, Thermo Scientific). For crosslinking, membranes from
1,000 oocytes were isolated as previously described [19], but using
20 mM HEPES-NaOH (pH 7.5) instead of 20 mM Tris-HCl
(pH 8) in all buffers. This is necessary because Tris contains a
primary amine that competes with amine-reactive crosslinkers
such as DST. Total protein concentration of oocyte membranes
was adjusted to 1 mg/ml. Chemical crosslinking with DST was
performed at four different concentrations: 100 mM, 250 mM,
500 mM and 1000 mM of DST for 15 min at 15uC, and at a total
protein concentration of 100 mg/ml. The crosslinking reaction was
terminated by adding glycine to a final concentration of 50 mM.
Equal volumes of 56SDS sample buffer were then added to the
reaction mixtures. In Figure 4, ,450 ng of total protein were
loaded on a 6% SDS/polyacrylamide gel and subjected to SDS-
PAGE and immunoblotting.
Results and Discussion
Frog oocytes have been shown to be ideal for expression and
purification of human membrane transporters [19]. Purified
proteins of different recombinant transporters were of high quality
Figure 2. Purification and biochemical characterization of
recombinant hSVCT1. Silver-stained SDS/polyacrylamide gels of
detergent-solubilized membranes prior binding to cobalt resin (A)
and purified hSVCT1 after metal affinity chromatography (B). A
prominent hSVCT1 band is discerned between the 50 and 75 kDa
markers. (C) Western blot analysis of PNGase F untreated (2) and
treated (+) purified hSVCT1. A clear shift towards lower molecular mass
and a more compact appearance of the hSVCT1 monomer and dimer
bands is observed after PNGase F treatment of purified protein. This
indicates N-linked glycosylation of hSVCT1 when expressed in Xenopus
laevis oocytes. In (A)-(C) samples were run on 6% SDS/polyacrylamide
gels, and in the Western blot displayed in (C) an anti-HA antibody was
used.
doi:10.1371/journal.pone.0076427.g002
Figure 3. Negative stain-TEM and SPA of purified hSVCT1. (A)
Overview electron micrograph of purified hSVCT1 adsorbed on a
parlodion carbon-coated surface. Projections of differently oriented
hSVCT1 proteins are discerned. Large, elliptical (hSVCT1 dimers) and
small, round-shaped (hSVCT1 monomers) particles are marked by black
and white circles, respectively. Small protein aggregates are also
observed (arrowheads). Well-preserved top views of dimers (B) and
monomers (C) were magnified and are displayed in the gallery. The
rightmost frames in (B) and (C) display averages of dimer (n = 387) and
monomer (n = 316) top views, respectively. In hSVCT1 dimers (B) two
stain accumulations are discerned, while in monomers (C) only one.
Averages are low-pass filtered to 2 nm resolution. The scale bar in (A) is
100 nm. The frame sizes in (B) and (C) are 18.5 nm.
doi:10.1371/journal.pone.0076427.g003
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and the isolated amounts suitable for structural analysis by
transmission electron microscopy (TEM) and single particle
analysis (SPA) [19]. Compared to most expression systems, which
work in cell culture, the effort is higher because single oocytes have
to be injected with cRNA. However, advances in automatization
have been done during the last years, making the cRNA-
microinjection of a few thousand oocytes per day possible. Here,
automated injection of Xenopus oocytes was applied for expres-
sion of hSVCT1.
Expression and Function of hSVCT1 in Xenopus Oocytes
The cDNA of hSVCT1 was cloned into the oocyte expression
vector pMJB08 [19]. Expression results in a recombinant protein
with decahistidine tag, and FLAG and HA epitopes at the N-
terminus. In addition, a PreScission protease cleavage site is
present between the FLAG and HA epitopes. Following the
method by Bergeron et al. [19], cRNA was injected into frog
oocytes (20 ng per oocyte) and protein expression tested after three
days of incubation at 18uC. Figure 1A displays a representative
Western blot of isolated total membranes from 3 oocytes with a
prominent band visible between the 50 and 75 kDa markers. This
band corresponds to recombinant hSVCT1, which has a
calculated molecular mass of ,71 kDa based on the amino acid
sequence. A second weaker band was visible between the 100 and
150 kDa markers, thus about twice the molecular mass of the
previous one and corresponding to hSVCT1 dimers. In a next
step, uptake experiments using water-injected and hSVCT1
cRNA-injected oocytes, and radiolabeled vitamin C were
performed. As shown in Figure 1B, cRNA-injected oocytes clearly
indicated uptake of [14C]vitamin C and thus functionality of
recombinant hSVCT1.
Purification and Biochemical Characterization of
Recombinant hSVCT1
For protein purification, total membranes from 1,200–5,000
oocytes expressing hSVCT1 were isolated and solubilized with the
non-ionic, mild detergent Triton X-100. After ultracentrifugation,
the supernatant (Fig. 2A) containing detergent-solubilized, His-
tagged hSVCT1 was subjected to cobalt affinity chromatography.
hSVCT1 was then specifically detached from the resin by on-
column cleavage with the protease PreScission, i.e., by removal of
the N-terminal end containing the His-tag. Because this protease is
His-tagged and binds to the cobalt resin, cleaved hSVCT1 could
be eluted from the chromatography column without contamina-
tion from PreScission. Protein yields from five independent
hSVCT1 expressions/purifications were 6, 6, 16, 22 and 48 mg
from 1,200, 1,500, 5,000, 3,500 and 5,000 injected oocytes,
respectively. From these numbers an average expression of ,6 ng
of hSVCT1 per oocyte was estimated. Figure 2B displays a typical
silver-stained SDS/polyacrylamide gel of purified hSVCT1
documenting the high purity of the isolated protein. Similar to
Figure 1A, hSVCT1 migrated between the 50 and 75 kDa
markers. A hSVCT1 dimer band was not obvious in the silver-
stained gel (Fig. 2B) due to the low abundance of the dimer and
the detection limit of silver staining. However, a hSVCT1 dimer
band was observed on Western blots of purified hSVCT1 (Fig. 2C,
-) indicating the presence of a minor population of hSVCT1
dimers. Importantly, there were no indications for protein
degradation or contamination (Fig. 2B). Diffuse bands were
characteristic of hSVCT1 on SDS-PAGE gels. To test, if the
diffuse bands arose from N-linked glycosylation of the protein,
purified hSVCT1 protein was incubated with the endoglycosidase
PNGase F and subjected to Western blot analysis (Fig. 2C).
Compared to untreated (Fig. 2C, -), PNGase F-treated (Fig. 2C, +)
hSVCT1 clearly indicated a change in migration towards lower
molecular mass and a more compact appearance of hSVCT1
bands on Western blots. This supports the presence of N-linked
glycosylation in hSVCT1 expressed in frog oocytes.
TEM and SPA of Purified Recombinant hSVCT1
For structural analysis, purified hSVCT1 was negatively stained
and examined in the TEM. Figure 3A displays a typical electron
micrograph of hSVCT1 protein adsorbed on a carbon-coated
parlodion grid. Because proteins can adsorb in different orienta-
tions on a support, their projections on electron micrographs
reflect different views of the protein, e.g., top and side views. Two
distinct top view populations of particles were found: larger,
elliptical particles with two stain accumulations (Fig. 3A, black
circles) and smaller, round-shaped particles with a central stain
accumulation (Fig. 3A, white circles). Small protein aggregates
were also observed (Fig. 3A, arrowheads). The galleries in Figure 3
display selections of well-preserved top views of larger (B) and
smaller (C) hSVCT1 particles. The rightmost frames in these two
galleries are calculated averages of the corresponding particle
populations. From these averages, dimensions of ,8.2 nm x
,11.1 nm were estimated for the larger, elliptical particles and a
diameter of ,7.7 nm for the smaller, round-shaped particles.
Dimensions, shapes and low-resolution structures of the two
distinct particle populations suggest the presence of monomeric
and dimeric hSVCT1 when purified in detergent. Estimated from
Figure 4. Chemical crosslinking of hSVCT1 in isolated oocyte
membranes. Western blot analysis of isolated oocyte membranes
containing hSVCT1 incubated at different DST concentrations, i.e., 0,
100, 250, 500 and 1000 mM. hSVCT1 monomer (M), dimer (D) and
aggregate (A) bands are indicated. At $250 mM DST increasing
smearing (S) and aggregation, and decreasing amounts of monomers
are observed indicating unspecific crosslinking. Western blotting was
performed using a 6% SDS/polyacrylamide gel and an anti-HA antibody.
The interface between stacking and separating gels is indicated (dotted,
white line).
doi:10.1371/journal.pone.0076427.g004
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particles on electron micrographs (Fig. 3A), dimers were minor
compared to monomers.
Chemical Crosslinking of hSVCT1 in Isolated Oocyte
Membranes
To explore if dimeric hSVCT1 proteins also exist in
membranes, chemical crosslinking experiments of isolated oocyte
membranes expressing hSVCT1 with the homobifunctional
crosslinker disuccinimidyl tartarate (DST; spacer arm 6.4 A˚) were
performed. Figure 4 displays a Western blot of isolated oocyte
membranes containing hSVCT1 incubated at different concen-
trations of DST. In contrast to membranes incubated in the
absence of DST (Fig. 4, lane 1), the presence of crosslinker induced
hSVCT1 dimer formation (Fig. 4, lanes 2–5; dimer band: D).
Although not clearly visible in Fig. 4, lane 1 a minor population of
SDS-resistant hSVCT1 dimers (relatively to monomers) is present
on SDS-PAGE gels of non-crosslinked membranes (see Fig. 1A for
a longer developed blot). Optimal conditions were at 100 mM
DST, where basically only hSVCT1 monomers and dimers were
detected (Fig. 4, lane 2). At 250, 500 and 1000 mM (Fig. 4, lanes 3–
5) increasing smearing (S) and amounts of aggregation (band: A),
and decreasing amounts of monomer (band: M) were observed.
Smearing and aggregation below the stacking and separating gel
interface (Fig. 4; dotted, white line) are characteristic of cross-
linking due to random collision, i.e, unspecific crosslinking
between hSVCT1s and other proteins of varying molecular
masses. In summary, crosslinking indicated the presence of
hSVCT1 dimers in isolated membranes, although at significant
lower amounts compared to monomeric hSVCT1 (Fig. 4, lane 2).
Conclusion
Expression, purification and structure determination of human
membrane proteins remains a great challenge. Isolation of
microgram amounts of recombinant protein made possible the
determination of shapes, dimensions, low-resolution structures and
oligomeric states of hSVCT1. To our knowledge, this is the first
report on the successful purification of a SLC23 gene family
member and paves the path for future functional and structural
studies using purified hSVCT1, e.g., functional reconstitution and
crystallization.
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